Investor Relations

Investor Overview

KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.


Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
09/26/16 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
KemPharm, Inc. Provides Corporate and Clinical Update
KemPharm to Present Data at PAINWeek 2016
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources